2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.18

PP02.18 - Huixin Jiang

Pdf Summary

This study examines the safety and effectiveness of cadonilimab, a bispecific PD-1/CTLA-4 antibody, in combination with chemotherapy for treating advanced/metastatic non-small cell lung cancer (NSCLC) with STK11 mutation. The presence of the STK11 genetic mutation in NSCLC is associated with reduced PD-L1 expression and poor response to traditional treatments, leading to lower progression-free and overall survival rates. By combining cadonilimab with chemotherapy, the researchers hypothesize that antitumor immunity can be enhanced, potentially improving survival outcomes for these patients.<br /><br />Conducted at the First Affiliated Hospital of Guangzhou Medical University, this is a single-center, open-label, single-arm Phase II clinical trial. It aims to enroll treatment-naïve NSCLC patients with STK11 mutations. Participants will receive a combination of cadonilimab and chemotherapy, specifically pemetrexed and carboplatin for non-squamous NSCLC, or abraxane and carboplatin for squamous NSCLC, over four cycles. Maintenance therapy will follow for those who tolerate the initial treatment and show no disease progression.<br /><br />The main objectives of the study are to assess the objective response rate (ORR) and the treatment's safety. Secondary measures include progression-free survival (PFS), disease control rate, and response duration according to predefined clinical criteria. The study has been registered under the clinical trial identification number NCT06331650. Given the unique challenges posed by STK11 mutations, the study represents an innovative approach to improving outcomes for a difficult-to-treat segment of NSCLC patients.

Keywords

cadonilimab

bispecific antibody

PD-1/CTLA-4

chemotherapy

NSCLC

STK11 mutation

clinical trial

objective response rate

progression-free survival

antitumor immunity